Belantamab mafodotin (Blenrep), pomalidomide (Pomalyst), and dexamethasone (BPd) was well tolerated and led to deep responses in patients with high-risk multiple myeloma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback